- Home
- CRBU vs TARA Comparison
CRBU vs TARA Comparison
Compare CRBU & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- TARA
- Stock Information
- Founded
- CRBU 2011
- TARA N/A
- Country
- CRBU United States
- TARA United States
- Employees
- CRBU N/A
- TARA N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBU Health Care
- TARA Health Care
- Exchange
- CRBU Nasdaq
- TARA Nasdaq
- Market Cap
- CRBU 203.9M
- TARA 196.8M
- IPO Year
- CRBU 2021
- TARA N/A
- Fundamental
- Price
- CRBU $2.08
- TARA $4.28
- Analyst Decision
- CRBU Strong Buy
- TARA Strong Buy
- Analyst Count
- CRBU 3
- TARA 6
- Target Price
- CRBU $9.33
- TARA $19.80
- AVG Volume (30 Days)
- CRBU 4.6M
- TARA 375.1K
- Earning Date
- CRBU 11-07-2025
- TARA 11-03-2025
- Dividend Yield
- CRBU N/A
- TARA N/A
- EPS Growth
- CRBU N/A
- TARA N/A
- EPS
- CRBU N/A
- TARA N/A
- Revenue
- CRBU $9,121,000.00
- TARA N/A
- Revenue This Year
- CRBU $8.06
- TARA N/A
- Revenue Next Year
- CRBU N/A
- TARA N/A
- P/E Ratio
- CRBU N/A
- TARA N/A
- Revenue Growth
- CRBU N/A
- TARA N/A
- 52 Week Low
- CRBU $0.66
- TARA $2.21
- 52 Week High
- CRBU $3.54
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- CRBU 39.13
- TARA 35.78
- Support Level
- CRBU $2.28
- TARA $4.96
- Resistance Level
- CRBU $3.53
- TARA $5.31
- Average True Range (ATR)
- CRBU 0.27
- TARA 0.29
- MACD
- CRBU -0.07
- TARA -0.18
- Stochastic Oscillator
- CRBU 7.81
- TARA 11.62
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).